Skip to main content
. 2016 Jun 7;24(2):109–116. doi: 10.3727/096504016X14611963142254

Figure 3.

Figure 3

miR-34b targeted to HSF1 in AML cells. (A) Predicted binding site of miR-34b on target gene HSF1 using the algorithm miRanda. (B) Relative expression of HSF1 in blood sample of AML patients (n = 16) and healthy controls (n = 12). (C) HSF1 protein level in AML patients with different subtypes according to the FAB classification. (D) miR-34b expression in AML cell lines (HL-60 and OCI-AML3) and normal blood normal blood cells from healthy donors (n = 12). Each experiment was repeated in triplicate. *p < 0.05 versus CD11b cell, #p < 0.05 versus CD14 cell. (E) HSF1 expression in AML cells in response to the administration of miR-34b mimics. (F) Luciferase assay analysis of the binding of miR-34b on HSF1 3′-UTR. HSF-wt-UTR and HSF1-mut-UTR reporter plasmids together with miR-34b mimics were transfected into HL-60 cells, and the relative luciferase activities were determined.